BioHarvest Sciences (BHST) Projected to Post Quarterly Earnings on Tuesday

BioHarvest Sciences (NASDAQ:BHST) is projected to post its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect BioHarvest Sciences to post earnings of ($0.11) per share and revenue of $9.2390 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:30 PM ET.

BioHarvest Sciences Trading Up 0.9%

BHST opened at $4.31 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.35 and a quick ratio of 1.02. BioHarvest Sciences has a fifty-two week low of $4.10 and a fifty-two week high of $12.80. The firm has a market capitalization of $70.77 million, a PE ratio of -6.34 and a beta of 1.14. The company’s 50-day moving average is $4.69 and its 200 day moving average is $6.79.

Institutional Trading of BioHarvest Sciences

A number of large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in BioHarvest Sciences in the fourth quarter worth about $60,000. Geode Capital Management LLC bought a new position in shares of BioHarvest Sciences during the 4th quarter valued at approximately $61,000. HRT Financial LP bought a new position in shares of BioHarvest Sciences during the 4th quarter valued at approximately $75,000. Marshall Wace LLP purchased a new stake in shares of BioHarvest Sciences during the 4th quarter worth approximately $110,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of BioHarvest Sciences during the 4th quarter worth approximately $140,000.

Analysts Set New Price Targets

A number of analysts have commented on the company. Roth Mkm started coverage on BioHarvest Sciences in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.